Mpox-linked stocks extend rally into second week
Aug 19 (Reuters) -Shares of some mpox vaccine and drug developers jumped sharply on Monday in premarket trading, putting them on track to extend gains from last week as concerns over an outbreak of the virus rise.
Shares of GeoVax Labs GOVX.O and Tonix Pharmaceuticals TNXP.O led the gains. Both the companies, which have a combined market capitalization of less than $50 million, do not have any products on the market.
GeoVax's shares rose 47.9% to $10.44, while Tonix jumped 41% to 63 cents.
Emergent BioSolutions' shares EBS.N rose 5.4% to $11.32 premarket. Its vaccine, approved for smallpox, has been used as an mpox shot, but the U.S. Food and Drug Administration is yet to approve its application for use against the virus.
A new variant of mpox has spread rapidly in Africa, prompting the World Health Organization to declare mpox a global public health emergency last Wednesday.
Europe's disease prevention agency said on Friday more imported cases will appear in the region, a day after Sweden reported its first case of mpox linked to the new strain.
Danish-listed shares of Bavarian Nordic BAVA.CO, which makes an mpox vaccine, were down 4.1% at 271.80 Danish crowns ($40.22). They had jumped 20% on Friday, and rose 50% last week on growing concerns over the virus.
Siga Technologies' shares SIGA.O were up 1.3%. The stock fell nearly 20% on Thursday after the company's mpox drug failed to meet the main goal in a study.
($1 = 6.7584 Danish crowns)
Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
